

## **Financial Summary - 2013**





|                          | YTD 20:     | 13     | YTD 2012   |  |
|--------------------------|-------------|--------|------------|--|
| Net Sales                | 2,520.2     | (3.1)  | 2,599.9    |  |
| Pharma                   | 2,325.4     | (4.3)  | 2,429.3    |  |
| Ostocalcium (CH)         | 43.8        | (14.2) | 51.0       |  |
| Iodex (CH)               | 141.5       | 41.5   | 100.0      |  |
| Exports                  | 9.5         | (51.7) | 19.6       |  |
| Other Operating Income   | 26.0        |        | 26.5       |  |
| % to Sales               | 1%          |        | 1%         |  |
| Pharma                   | 15.1        |        | 16.0       |  |
| Other Businesses         | 10.9        |        | 10.5       |  |
| Total Materials consumed | 1,157.8     |        | 1,097.9    |  |
| % to Sales               | <b>46</b> % |        | <i>42%</i> |  |
| Gross Margin             | 1,362.4     | (9.3)  | 1,502.0    |  |
| % to Sales               | <i>54%</i>  |        | <i>58%</i> |  |
| Pharma                   | 1,233.9     |        | 1,387.7    |  |
| % to Sales               | <i>53%</i>  |        | <i>57%</i> |  |
| Other Businesses         | 128.5       |        | 114.3      |  |

## **Financial Summary - 2013**





|  | YTD 201 | L3     | YTD 2012   |
|--|---------|--------|------------|
| Employee Benefits                                | 362.1   | (22.5) | 295.5      |
| % to Sales                                       | 14%     |        | 11%        |
| Pharma   | 341.0   |        | 276.2      |
| Other Businesses                                 | 21.0    |        | 19.3       |
| Opex   | 549.2   | (18.6) | 463.2      |
| Pharma   | 434.3   | (11.3) | 390.3      |
| Other Businesses                                 | 106.7   | (39.5) | 76.5       |
| Excise duty on Inventory changes                 | 8.2     |        | (3.6)      |
| Depreciation                                     | 19.9    |        | 17.8       |
| % to Sales                                       | 1%      |        | 1%         |
| Pharma   | 17.7    |        | 15.8       |
| Services   | 2.2     |        | 2.0        |
| Recovery of Expenses for Services                | (45.0)  |        | (45.4)     |
| Opex (Net of Recovery) & Depreciation % to Sales | 21%     |        | <i>17%</i> |

# **Financial Summary - 2013**





|                                  | YTD 20:     | 13     | YTD 2012    |
|----------------------------------|-------------|--------|-------------|
| <b>Profit from Operations</b>    | 502.2       | (37.0) | 797.4       |
| % to Sales                       | <b>20%</b>  |        | <i>31%</i>  |
| Pharma                           | 446.7       | (38.2) | 723.3       |
| Other Businesses                 | 55.5        | (25.1) | 74.1        |
| Investment Income / Other Income | 201.0       |        | 197.4       |
| PBT before Exceptionals          | 703.2       | (29.3) | 994.8       |
| % to Sales                       | <b>28</b> % |        | <i>38%</i>  |
| Exceptional Items (Gross)        | 26.1        |        | (148.2)     |
| РВТ                              | 729.3       |        | 846.6       |
| % to Sales                       | <b>29</b> % |        | <i>33</i> % |
| PAT                              | 501.9       | (13.1) | 577.3       |
| % to Sales                       | <b>20</b> % |        | <i>22%</i>  |



INR Cr

#### **SBU** wise Sales Performance

| SBU VERTICALS   | FY'13  | Gr%   |
|-----------------|--------|-------|
| Mass Markets    | 797    | -12%  |
| Mass Specialty  | 577    | -12%  |
| Speciality      | 590 99 |       |
| Derma           | 455    | 7%    |
| Others          | 135    | 14%   |
| Vaccines        | 362    | 12%   |
| <b>Total Rx</b> | 2,325  | -4.3% |

Financial Results FY 2013

## **Exceptional Items**





|  | 2013    |
|--|---------|
|  |         |
| Thane Operating Costs (Net)                | 2.19    |
| Write back of provisions for formulations  | (5.63)  |
| Profit on sale of property                 | (21.18) |
| Actuarial gain/(loss) on employee benefits | (1.53)  |
|  | (26.15) |

### **Cash Flow**





| Cash                | FIOW  |                  |                  |
|---------------------|---|------------------|------------------|
| INR Cr              |   | 2013             | 2012             |
|                     | Profit before taxation and exceptional items                                    | 703              | 995              |
|                     | Depreciation and other non-operating activities                                 | (180)            | (179)            |
|                     | Operating profit before working capital changes                                 | 523              | 816              |
|                     | Adjustments for :   |                  |                  |
|                     | Inventories Sundry Debtors Trade payables and other liabilities net of advances | (60)<br>20<br>43 | 47<br>(28)<br>20 |
|                     | Cash generated from operations  | 524              | 855              |
|                     | Taxes Paid  | (242)            | (314)            |
|                     | Capex   | (52)             | (39)             |
|                     | Investment Income   | 197              | 180              |
|                     | Redemption of Investments  Movement in bank deposits (having original maturity  | 45               | 57               |
|                     | more than 3 months)   | (13)             | (291)            |
|                     | Cash flow before exceptional items  | 459              | 448              |
|                     | Exceptional items:  |                  |                  |
|                     | Payments under Voluntary Retirement Scheme DPEA Interest                        | (4)<br>-         | (91)<br>(137)    |
|                     | Thane operating costs   | (11)             | (19)             |
|                     | Payment received for sale of flat Dividend etc                                  | 21<br>(490)      | -<br>(437)       |
| estal Bassilas O4 1 | Net decrease in cash and cash equivalents                                       | (24)             | (236)            |

#### **Financial Performance**



#### **EPS and Book Value per share (INR)**





#### **Return on Avg. Net Worth**

